Ziftomenib
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 45 publications
Targeting the Menin-KMT2A Axis in AML: Translating Molecular Insights into Therapeutic Success.
Journal: Clinical lymphoma, myeloma & leukemia
Published: June 03, 2026
Emerging drug profile: menin inhibitors in NPM1-mutated and KM2A-rearranged acute myeloid leukemia.
Journal: Leukemia & lymphoma
Published: May 27, 2026
Combined Menin and XPO1 inhibition drive synergistic antileukemic activity in KMT2Ar and NPM1-m AML.
Combined Menin and XPO1 inhibition drive synergistic antileukemic activity in KMT2Ar and NPM1-m AML.
Journal: bioRxiv : the preprint server for biology
Published: April 10, 2026
A Practical Alternative to Refine the Estimate of fmCYP3A4 and Evaluate Drug-Drug Interaction Potential for Ziftomenib Using PBPK Modeling to Inform Labeling.
Journal: CPT: pharmacometrics & systems pharmacology
Published: April 03, 2026
Ziftomenib (Komzifti) for acute myeloid leukemia.
Journal: The Medical letter on drugs and therapeutics
Published: March 07, 2026
Differentiation therapy in acute myeloid leukaemia: molecular basis, clinical progress, and future perspectives.
Journal: Frontiers in medicine
Published: February 26, 2026
Targeted Therapy in Acute Myeloid Leukemia: Current Approaches and Novel Directions.
Journal: Journal of personalized medicine
Published: February 16, 2026
Targeting the Menin-KMT2A Axis in Acute Leukemia: From Epigenetic Dependency to Clinical Translation.
Journal: European journal of haematology
Published: January 29, 2026
Menin inhibitors as a treatment for acute leukemia: from bench to the clinic.
Journal: Blood neoplasia
Published: January 28, 2026
Last Updated: 09/26/2026